Trump's pharma tariff pivot hits Australian and India drugmakers

Shares volatile after US president indicates levy will be brought forward

20250716 Pharmaceutical company manufacturing

Employees work inside a Cadila Pharmaceuticals manufacturing unit on the outskirts of Ahmedabad, India, on April 12. © Reuters

SHAUN TURTON and SAYAN CHAKRABORTY

MELBOURNE/BENGALURU -- U.S. President Donald Trump dealt Asian markets a fresh bout of volatility on Wednesday after he said pharmaceutical imports would face tariffs by "the end of the month," having earlier given a much longer time frame for the move.

Trump last week flagged a potential 200% levy on foreign medicines imported into the U.S but said drug manufacturers would be given up to a year and a half before it was implemented.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.